Clinical practice effect of rosiglitazone discontinuation on glycemic control

Endocrine Practice

Volumn 15, Issue 3, 2009, Pages 270-272

  Fanning, Etta L ^a,d   Weissman, Peter N ^b   Menditto, Laura A ^c  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c GLAXOSMITHKLINE   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA;

ADULT; AGED; CLINICAL PRACTICE; COMBINATION CHEMOTHERAPY; DRUG EFFECT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE;

EID: 67649199624     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.15.3.270     Document Type: Note

References (15)

1. Kahn SE, Haffner SM, Heise MA, et al; the ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy [erratum in N Engl J Med. 2007;356:1387-1388]. N Engl J Med.2006;355: 2427-2443.
2. Theheart.org from WebMD. VA Diabetes Trial shows that intensive glucose control has little effect on cardiovascular risk. Available at: http://www.theheart.org/article/print.do?primaryKey=875871. Accessed November 15, 2008.
3. DREAM (Diabetes Reduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, Gerstein HC, Yusuf S, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised control trial [erratum in Lancet. 2006;368:1770]. Lancet.2006;368:1096-1105.
4. ADVANCE Collaborative Group, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med.2008; 358:2560-2572.
5. Rosenstock J, Goldstein BJ, Vinik AI, et al; RESULT Study Group. Effect of early addition of rosiglitazone to sulfonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study. Diabetes Obes Metab.2006;8:49-57.
6. Home PD, Pocock SJ, Beck-Neilsen H, et al; RECORD Study Group. Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis. N Engl J Med.2007;357: 28-38.
7. Theheart.org from WebMD. APPROACH: Rosiglitazone doesn't affect atherosclerosis progression in diabetics with CV disease. Available at: http://www.theheart.org/view-Article.do?primaryKey=921219. Accessed November 13, 2008.
8. General Electric Centricity EMR and Healthcare. Available at: http:www.gehealthcare.com/centricity. Accessed September 27, 2008.
9. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
10. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin dependent diabetes mellitus: a randomized prospective 6-yer study. Diabetes Res Clin Pract. 1995;28:103-117.
11. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [erratum in Lancet. 1999:354:602.]. Lancet.1998;352:837-853.
12. Viberti G, Kahn SE, Greene DA, et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care.2002;25:1737-1743.
13. Yki-Järvinen H. Thiazolidinediones. N Engl J Med. 2004; 351:1106-1118.
14. Kahn SE, Haffner SM, Heise MA, et al; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy [erratum in N Engl J Med. 2007:356:1387-1388]. N Engl J Med. 2006;355: 2427-2443.
15. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia.2003;46:3-19.